Smear Campaign: Misattribution of Pancytopenia to a Tick-Borne Illness
We report the case of a 51-year-old woman presenting with a targetoid rash and pancytopenia after a tick bite. Initial evaluation was notable for severe neutropenia on the complete blood cell count differential, a positive Lyme IgM antibody, and a peripheral blood smear demonstrating atypical lymphocytes. While her pancytopenia was initially attributed to tick-borne illness, peripheral flow cytometry showed 7% myeloblasts, and a bone marrow biopsy confirmed 60% blasts. The patient was ultimately diagnosed with acute myelogenous leukemia, in addition to early, localized Lyme disease. This case highlights the differential diagnosis for pancytopenia, cytopenia patterns for different tick-borne illnesses, the risk of premature closure in internal medicine, and management of Lyme disease in hosts with altered immunity.
Publication date: Available online 1 August 2020Source: Ticks and Tick-borne DiseasesAuthor(s): Sissy-Christin Lorenz, Pascal Humbert, Anant V. Patel
Publication date: Available online 1 August 2020Source: Meta GeneAuthor(s): Rania A. Zayed, Zainab El-Saadany, Hanan Nour Raslan, Mohammed Ghareeb, Dalia Ibraheem, Marwa Rashed, Rania Kandil, Omnia Y. Abdeldayem
ConclusionSimultaneous administration of quizartinib and CYT every other day is a promising combination regimen for AML patients with FLT3 mutations.
Publication date: Available online 2 July 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Michael Rassner, Johannes Jung, Johanna Schneider, Ralph Wäsch, Monika Engelhardt
ConclusionsThe specific alteration of renal transporters and glomerular filtration in kidneys provide a rational explanation for changes in pharmacokinetics for ALL.
Broad implementation of engineered chimeric antigen receptor T-lymphocytes (CAR-T) targeting the CD19 surface antigen for the treatment of refractory and multiply relapsed B-cell precursor acute lymphoblastic leukemia (B-ALL) has been a major breakthrough in both pediatric oncology and the field of cellular therapy. Large trials of CD19-directed CAR-T products infused into heavily pre-treated pediatric patients, many of whom had undergone prior hematopoietic stem cell transplantation (HSCT), showed complete response (CR) rates between 66-89% with a reported 12 month event free survival (EFS) at or around 50% 1-3.
Publication date: Available online 1 August 2020Source: Journal of Microbiology, Immunology and InfectionAuthor(s): Tian Zhang, Jie Bai, Mingxia Huang, Ruixiao Li, Yang Liu, Jixin Liu, Ansheng Liu
Authors: Baek DW, Kim J, Cho HJ, Moon JH, Sohn SK Abstract INTRODUCTION: Clinical outcomes of patients diagnosed with high-risk acute myeloid leukemia (AML) are poor, and relapse or refractoriness is main cause of treatment failure, even in those who underwent standard allogeneic stem cell transplantation (allo-SCT). Therefore, innovative or additional approaches are necessary to overcome refractoriness to the graft-versus-leukemia (GVL) effect immediately after allo-SCT. AREAS COVERED: Hypomethylating agents (HMA) present a feasible option that can be adopted during the post-transplant phase. Moreover, combina...
SATURDAY, Aug. 1, 2020 -- Summer means higher odds of getting Lyme disease, so know how to avoid it, health experts say. Lyme disease is caused by a bacterium carried by some ticks and, if left untreated, can cause severe health problems. Ticks can...